Author ORCID Identifier

Date of Graduation


Document Type

Thesis (MS)

Program Affiliation

Genes and Development

Degree Name

Doctor of Philosophy (PhD)

Advisor/Committee Chair

Anil K. Sood, MD

Committee Member

Swathi Arur, PhD

Committee Member

Russell R. Broaddus, MD/PhD

Committee Member

Jeffrey N. Myers, MD/PhD

Committee Member

Jason Roszik, PhD/MBA


Re-purposing of targeted therapies for additional tumor types is a promising avenue for expanding treatment options for cancer patients, however accurately predicting what re-purposed targeted therapy will be effective remains challenging. To address this need, we developed a Therapy Predicting Tool (TPT) that accurately predicts the beneficial therapeutic effect of clinically relevant targeted therapies and the downstream pathways they may impact in the cancer of interest. Using ovarian cancer as a model to biologically validate our tool, we determined that Bromodomain and Extra-Terminal motif inhibitors (BETis), which target proteins such as BRD4, held the greatest promise to produce therapeutic effects and impact relevant oncogenic gene targets, such as Notch3, in this disease. In our pre-clinical models, we demonstrated that BETis produce therapeutic effects and prolong survival. Furthermore, we discovered that BRD4 directly regulates Notch3 transcription and its downstream targets in ovarian cancer. Our findings provide a basis for further exploration and application of our tool to identify and re-purpose targeted therapies for specific tumor types.


ovarian cancer, targeted therapies, BRD4, Notch3, Bromodomain and extraterminal domain inhibitors



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.